**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following President Trump’s December 2025 executive order directing expedited rulemaking.** This immediately moved FDA-approved products containing marijuana and state-licensed medical marijuana into Schedule III while preserving controls on illicit trafficking. A new administrative hearing on the broader proposed rule to reschedule all marijuana from Schedule I to Schedule III convened June 29, 2026, and concluded no later than July 15, 2026, under an expedited timeline. Legal challenges to the April order remain pending in the D.C. Circuit, and post-hearing steps—including any administrative law judge recommendation and final DEA action—introduce additional procedural layers. These developments shape trader views on timelines for full rescheduling, with the completed hearing and administration directives providing momentum while litigation and remaining administrative requirements create uncertainty around near-term completion.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড$796,429 Vol.
Mar 30, 2026
September 30
49%
December 31
27%
$796,429 Vol.
September 30
$0 Vol.
49%
December 31
$186,858 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following President Trump’s December 2025 executive order directing expedited rulemaking.** This immediately moved FDA-approved products containing marijuana and state-licensed medical marijuana into Schedule III while preserving controls on illicit trafficking.
A new administrative hearing on the broader proposed rule to reschedule all marijuana from Schedule I to Schedule III convened June 29, 2026, and concluded no later than July 15, 2026, under an expedited timeline. Legal challenges to the April order remain pending in the D.C. Circuit, and post-hearing steps—including any administrative law judge recommendation and final DEA action—introduce additional procedural layers.
These developments shape trader views on timelines for full rescheduling, with the completed hearing and administration directives providing momentum while litigation and remaining administrative requirements create uncertainty around near-term completion.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Feb 7, 2026, 5:04 PM ET
ভলিউম
$796,429শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following President Trump’s December 2025 executive order directing expedited rulemaking.** This immediately moved FDA-approved products containing marijuana and state-licensed medical marijuana into Schedule III while preserving controls on illicit trafficking.
A new administrative hearing on the broader proposed rule to reschedule all marijuana from Schedule I to Schedule III convened June 29, 2026, and concluded no later than July 15, 2026, under an expedited timeline. Legal challenges to the April order remain pending in the D.C. Circuit, and post-hearing steps—including any administrative law judge recommendation and final DEA action—introduce additional procedural layers.
These developments shape trader views on timelines for full rescheduling, with the completed hearing and administration directives providing momentum while litigation and remaining administrative requirements create uncertainty around near-term completion.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ভলিউম
$796,429শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following President Trump’s December 2025 executive order directing expedited rulemaking.** This immediately moved FDA-approved products containing marijuana and state-licensed medical marijuana into Schedule III while preserving controls on illicit trafficking. A new administrative hearing on the broader proposed rule to reschedule all marijuana from Schedule I to Schedule III convened June 29, 2026, and concluded no later than July 15, 2026, under an expedited timeline. Legal challenges to the April order remain pending in the D.C. Circuit, and post-hearing steps—including any administrative law judge recommendation and final DEA action—introduce additional procedural layers. These developments shape trader views on timelines for full rescheduling, with the completed hearing and administration directives providing momentum while litigation and remaining administrative requirements create uncertainty around near-term completion.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা